In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader (MGD), was shown to normalise multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers. Monte Rosa Therapeutics announced the finding along with other positive data from GFORCE-1, a Phase I study evaluating MRT-8102, which… Read More
Neomorph has commenced a Phase I/II clinical trial evaluating NEO-811, a novel investigational molecular glue degrader, in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC). NEO-811 is an investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein… Read More
Monte Rosa Therapeutics has shared positive interim data from an ongoing Phase I clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6. “These remarkable interim data from our ongoing Phase I study of… Read More
DDW Editor Reece Armstrong speaks to SJ Lee, Founder and CEO of Orum Therapeutics, about the potential of degrader-antibody conjugates (DACs) in treating previously “undruggable” diseases. RA: How do DACs work? SL: Degrader-antibody conjugates (DACs) combine two proven concepts—antibody precision and catalytic protein degradation—into a single, modular medicine. Read More
Monte Rosa Therapeutics has dosed the first subjects in a Phase I study evaluating MRT-8102, a NEK7-directed molecular glue degrader (MGD) being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6. Initial results from the Phase I study are expected in… Read More
Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer… Read More
According to new data, a cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader (MGD) drove deep tumour regression in preclinical models of HR-positive/HER2-negative breast cancer. Monte Rosa Therapeutics will present the preclinical data at the 2024 San Antonio Breast Cancer Symposium, held 10-13 December in San Antonio, Texas. Read More
